全文获取类型
收费全文 | 4139篇 |
免费 | 169篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 53篇 |
妇产科学 | 90篇 |
基础医学 | 566篇 |
口腔科学 | 102篇 |
临床医学 | 321篇 |
内科学 | 1097篇 |
皮肤病学 | 67篇 |
神经病学 | 275篇 |
特种医学 | 132篇 |
外科学 | 655篇 |
综合类 | 23篇 |
预防医学 | 133篇 |
眼科学 | 102篇 |
药学 | 155篇 |
中国医学 | 2篇 |
肿瘤学 | 511篇 |
出版年
2023年 | 33篇 |
2022年 | 54篇 |
2021年 | 98篇 |
2020年 | 45篇 |
2019年 | 68篇 |
2018年 | 101篇 |
2017年 | 65篇 |
2016年 | 70篇 |
2015年 | 77篇 |
2014年 | 108篇 |
2013年 | 109篇 |
2012年 | 172篇 |
2011年 | 201篇 |
2010年 | 123篇 |
2009年 | 81篇 |
2008年 | 144篇 |
2007年 | 183篇 |
2006年 | 171篇 |
2005年 | 149篇 |
2004年 | 140篇 |
2003年 | 160篇 |
2002年 | 145篇 |
2001年 | 124篇 |
2000年 | 122篇 |
1999年 | 117篇 |
1998年 | 32篇 |
1997年 | 26篇 |
1996年 | 24篇 |
1995年 | 37篇 |
1994年 | 27篇 |
1992年 | 115篇 |
1991年 | 118篇 |
1990年 | 92篇 |
1989年 | 98篇 |
1988年 | 66篇 |
1987年 | 74篇 |
1986年 | 62篇 |
1985年 | 62篇 |
1984年 | 36篇 |
1983年 | 30篇 |
1979年 | 36篇 |
1974年 | 61篇 |
1973年 | 42篇 |
1972年 | 40篇 |
1971年 | 38篇 |
1970年 | 42篇 |
1969年 | 47篇 |
1968年 | 46篇 |
1967年 | 36篇 |
1966年 | 23篇 |
排序方式: 共有4321条查询结果,搜索用时 15 毫秒
61.
Toshihiko Kotake Tsuneharu Miki Hideyuki Akaza Yoshinobu Kubota Yasunori Nishio Yosuke Matsumura Kazuo Ota Nobuya Ogawa 《Cancer chemotherapy and pharmacology》1991,27(4):253-257
Summary The effects of recombinant granulocyte colony-stimulating factor (rG-CSF) on the myelosuppression, especially neutropenia, induced by cancer chemotherapy in patients with urogenital cancer were investigated in a randomized, controlled clinical study. In this study, rG-CSF was given subcutaneously at a dose of 2 g/kg per day for 14 consecutive days. Changes in neutrophil counts were compared between the first (no rG-CSF) and second cycles (rG-CSF treatment period) of chemotherapy. rG-CSF administration was found to be effective in reducing the duration of neutropenia, in elevating the neutrophil nadir, and in reducing recovery time. Based on comparisons between the randomized rG-CSF treatment group (with rG-CSF) and the control group, treatment with rG-CSF resulted in the moderation or prevention of neutropenia and the acceleration of recovery. These results demonstrate that in chemotherapy of patients with urogenital cancer, in which neutropenia is a dose- or schedule-limiting factor, the concomitant use of rG-CSF may enable an increase in the dose (higher single dose or increased dose per unit of time) or shorten the chemotherapy period. 相似文献
62.
M Suminaga H Furue T Taguchi K Ota H Niitani S Tsukagoshi Y Ariyoshi M Ikeda Y Akasaka J Ohta 《Gan to kagaku ryoho. Cancer & chemotherapy》1992,19(11):1891-1903
We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin. Out of 84 cases where anti-emetic effects were evaluated, numbers of cases assessed as excellent and good were 36 (83.3%) and 34 (40.5%), respectively, the efficacy rate being 83.3% (70/84). Side effects, such as moderate constipation (3 cases) and mild headache (3 cases), were observed in 8/85 cases (9.4%). Abnormalities in clinical laboratory findings including elevation of hepatic function and uricacid values and increase in eosinocyte counts, were observed in 3/85 cases (3.5%). As to overall safety, 78/85 cases (91.8%) were evaluated as having no problem in safety, and 7/85 cases (8.2%), as having minor problem in safety. As to clinical usefulness based on anti-emetic effect and overall safety, out of 79 cases the drug was assessed as very useful in 29 cases (36.7%) and useful in 35 cases (44.3%), the rate of "useful" or above being 81.0% (64/79). Furthermore, when ondansetron was administered in 3 courses of chemotherapy, though the number of patients was small, it was shown that anti-emetic effect of ondansetron did not decline and no problem in safety was observed. From the above, ondansetron which exerted adequate anti-emetic effect in 4 mg once daily doses was considered as a useful and safe anti-emetic in treatment of nausea and emesis associated with cancer chemotherapy. 相似文献
63.
Takeshi Tominaga Hiroki Koyama Tetsuya Toge Shigeto Miura Keizo Sugimachi Susumu Yamaguchi Koichi Hirata Yasumasa Monden Yasuo Nomura Masakazu Toi Izo Kimijima Shinzaburo Noguchi Hiroshi Sonoo Kazuaki Asaishi Tadashi Ikeda Tadaoki Morimoto Jun Ota Yasuo Ohashi Osahiko Abe 《Journal of clinical oncology》2003,21(6):991-998
PURPOSE: We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy. PATIENTS AND METHODS: A total of 1,131 women with node-positive primary breast cancer were randomly assigned after primary surgery to receive 5'-DFUR alone or 5'-DFUR plus CPM. All patients initially received 5'-DFUR in an oral dose of 1,200 mg/d for 4 weeks, starting 4 weeks after surgery. Chemotherapy was then not given for 2 weeks. Patients in the 5'-DFUR group subsequently received five 4-week cycles of treatment consisting of oral 5'-DFUR (1,200 mg/d) for the first 2 weeks and no chemotherapy for the next 2 weeks. Those assigned to the 5'-DFUR plus CPM group also received oral CPM 100 mg/d for the first 2 weeks and no chemotherapy for the next 2 weeks. Women 50 years or older concurrently received 20 mg/d of tamoxifen for 2 years in both groups. RESULTS: Of the 1,088 eligible women, 546 were assigned to receive 5'-DFUR alone and 542 were assigned to receive 5'-DFUR plus CPM. Overall disease-free survival was significantly better in women who received 5'-DFUR plus CPM than in those who received 5'-DFUR alone (log-rank test, P =.021). Toxic effects occurred in 20.0% of patients (109 of 546) in the 5'-DFUR group and 32.3% of patients (175 of 542) in the 5'-DFUR plus CPM group (chi(2) test, P <.001). CONCLUSION: Combination therapy with 5'-DFUR plus CPM is more effective in preventing recurrence than 5'-DFUR alone. 相似文献
64.
Tani M Ozono S Takashima K Tanaka M Ota M Nagayoshi J Yoshikawa M Hirao Y Okajima E 《Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology》2000,91(4):469-472
PURPOSE: We investigated on a problem of long-term follow up in patients with renal cell carcinoma. PATIENTS AND METHODS: A total of 287 patients with renal cell carcinoma treated in Nara Medical University and affiliated facilities from January 1980 to December 1990 were examined. And we investigated the trend of explanation to patients including 287 patients from 1991 to 1995. RESULTS: Up to December 1995, there are 76 patients (26.5%) unable to be followed and 211 patients able to be followed. The former group patients were less declared cancer rather than the latter group patients. Of 76, 22 patients (28.9%) might misunderstand completely recovering from the cancer disease. For the recent 5 years, those patients who were declared cancer increased, and those patients who were explained benign disease decreased. CONCLUSION: These results suggested that declaration of cancer is important for patients with renal cell carcinoma to be followed for a long-term. 相似文献
65.
Haruka Uezono Kayoko Tsujino Keno Moriki Fumiko Nagano Yosuke Ota Ryohei Sasaki Toshinori Soejima 《Journal of radiation research》2013,54(6):1102-1109
The purpose of this study is to determine the incidence, clinical characteristics and risk factors of postradiation pelvic insufficiency fracture (PIF) in women with uterine cervical cancer. We reviewed the medical records of 126 patients who received definitive radiotherapy (RT) for uterine cervical cancer between 2003 and 2009 at our institution. Among them, 99 patients who underwent at least one computed tomography (CT) or magnetic resonance imaging of the pelvis during their follow-up at more than 6 months were included in this analysis. The relationship between the incidence of PIF and several patient- and treatment-related factors was analyzed. The median follow-up period was 21 months. Of the 126 patients, 33 (with a total of 50 lesions) were diagnosed with PIF. The 2-year cumulative incidence was 32%. Univariate analysis showed that age ≥70 years (P= 0.0010), postmenopausal state (P = 0.0013), and lower CT density of bone and bone marrow (P= 0.020) significantly related to PIF. In a multivariate analysis, of the 59 patients whose CT densities were evaluable, lower CT density was the only significant factor associated with PIF (P = 0.0026). In conclusion, postradiation PIFs were detected in a considerable number of patients after definitive RT for cervical cancer. Predisposing factors were older age, postmenopausal state, and decreased density of bone and bone marrow on CT. 相似文献
66.
67.
68.
69.
Kosuke Nomura Toshiro Iizuka Daisuke Kaji Hisashi Yamamoto Yasutaka Kuribayashi Ryusuke Kimura Akihiro Yamada Tsukasa Furuhata Satoshi Yamashita Daisuke Kikuchi Akira Matsui Toshifumi Mitani Osamu Ogawa Shu Hoteya Yasunori Ota Shuichi Taniguchi Mitsuru Kaise 《Journal of gastroenterology and hepatology》2014,29(11):1867-1872
70.
Shuichi Ota Toshihiro Matsukawa Satoshi Yamamoto Shinichi Ito Motohiro Shindo Kazuya Sato Takeshi Kondo Kyuhei Kohda Hajime Sakai Akio Mori Tohru Takahashi Hiroshi Ikeda Hiroyuki Kuroda Yoshihito Haseyama Masaki Yamamoto Takeo Sarashina Makoto Yoshida Ryoji Kobayashi Mitsufumi Nishio Toshimichi Ishihara Yasuo Hirayama Yasutaka Kakinoki Hajime Kobayashi Takashi Fukuhara Masahiro Imamura Mitsutoshi Kurosawa 《European journal of haematology》2018,101(1):95-105